Grifols — August 2026

Its stock is cited among the biggest decliners in a session of the Spanish market.

The pharmaceutical company appears among the worst-performing Ibex 35 stocks in a trading session shaped by tension in the Middle East.

The company is listed as one of the declining stocks in a daily roundup of Ibex 35 quotations.

Grifols is mentioned tangentially among Ibex 35 stocks in a report on the market's performance during the trading session.

The pharmaceutical company appears as an example of a firm that resumed dividend payments after a suspension period linked to balance-sheet repair.

It is cited as an example of a Spanish pharmaceutical company with business in the United States, with no involvement in the investigation.

The pharmaceutical company appears in a stock market table as one of the Ibex 35 shares that closed the session with a decline.

The pharmaceutical company is listed among the Ibex 35 firms with the highest share of sales generated outside Spain.

The company appears in the Ibex 35 stock listing with a slight decline during the trading session.

The pharmaceutical company is listed as one of the Ibex 35 stocks that declined during the trading session.

The company appears as one of the stocks with the largest decline in the Ibex 35 trading session covered in the news.

The company appears among the worst-performing stocks in the daily session of the Ibex 35.

The company is listed among the worst-performing stocks in a trading session of the Ibex 35 index.

The company appears among the worst-performing stocks in the day's trading session.

The pharmaceutical company is listed among the declining stocks on the Ibex 35 during a trading session.

The pharmaceutical company appears among the Ibex 35 stocks with a decline in the daily trading session.

The pharmaceutical company is mentioned as one of the firms added to the Ibex 35 index in recent decades.

The pharmaceutical company is cited as a comparative reference for its high stock market upside potential within the index.

The company is cited as one of the large listed Catalan firms whose aggregate profits are analyzed in a union report.

The company is cited as one of the Catalan listed firms with high profits in a union report on wage inequality.

The company is cited as one of the large listed Catalan firms with millionaire profits in a union study on wage inequality.

Grifols is mentioned tangentially as one of the Ibex 35 stocks in a daily report on stock market performance.

The company appears as one of the stocks with a moderate decline in the Ibex 35 trading session.

The pharmaceutical company is mentioned over its German subsidiary's commercial ties with Iranian entities in plasma supply.

The company appears as one of the Ibex 35 listed stocks declining during the trading session.

Its stock performance is mentioned as one of the decliners in the Ibex 35 trading session.

The pharmaceutical company appears among the Ibex 35 stocks with a slight decline in its share price during the trading session.

The pharmaceutical company appears among the Ibex 35 stocks with a slight decline in a trading session reported by the outlet.

The pharmaceutical company is the plaintiff in a defamation lawsuit against a short-selling fund and its critical report.

The company is the party benefiting from a court ruling that denies legal protection sought by its accusers.

The company appears as the party benefiting from a court ruling that denies journalist-source protection to its accuser.

The company appears among the Ibex 35 stocks with the largest decline in the trading session analyzed.

The company appears as one of the Ibex-35 stocks with the worst performance in the daily trading session.

The company appears among the Ibex 35 stocks with a decline in the daily trading session.

The company appears among the Ibex 35 stocks that fell in the weekly closing of the Spanish stock market.

The pharmaceutical company is listed among the Ibex 35 stocks with the sharpest declines during the trading session.

Grifols is mentioned as one of the Ibex 35 stocks in an article about the performance of the Spanish stock market amid geopolitical tensions.

The pharmaceutical company is mentioned as one of the worst-performing stocks at the opening of the Ibex 35 trading session.

Grifols is mentioned tangentially among Ibex 35 stocks in the report on the opening of the trading session.

The pharmaceutical company appears as one of the biggest decliners at the opening of the Ibex 35 trading session.

The pharmaceutical company is listed among the biggest decliners at the opening of the Ibex 35 session.

The pharmaceutical company is listed among the Ibex 35 stocks with the biggest drop at the market's opening.

The pharmaceutical company is mentioned as an example of the lengthy regulatory process separating a laboratory finding from an approved drug.

The pharmaceutical company is mentioned among the Ibex 35 stocks that rose, offsetting broader losses in the Spanish stock market.

The company is listed among the stocks with the largest percentage gain on the Spanish stock index that session.

The pharmaceutical company is listed among the Ibex-35 stocks with the largest percentage gain in the trading session.

The pharmaceutical company is mentioned as one of the top-performing stocks on the Ibex 35 during a session of overall index decline.

The company is listed among the Ibex 35 stocks with the highest percentage gains in the day's trading session.

The company appears among the stocks with the worst performance on the Spanish stock index during the session.

The company is listed as one of the Ibex 35 stocks in a market report on the Spanish stock exchange amid geopolitical tension in the Middle East.

The pharmaceutical company appears among the stocks that recorded declines at the opening of the trading session.

The company appears in a stock market listing as one of the Ibex-35 shares falling at the session's opening.

The company appears as one of the stocks with slight declines in the Ibex 35 trading session.

The company is mentioned in passing among Ibex 35 stocks in a review of the trading session's performance.

The company appears as one of the declining stocks in the Ibex 35 trading session.

The company appears in a stock market listing as one of the shares with a slight drop at market open.

The pharmaceutical company appears among the worst-performing stocks on the Ibex 35 at the start of the trading session.

The company appears as one of the worst-performing stocks in the Ibex 35 trading session.

The pharmaceutical company appears in a list of stock market values with moderate losses during a session of the Spanish market.

The pharmaceutical company is listed among the Ibex 35 stocks with a slight drop at the market opening.

The company is listed among the worst-performing Ibex 35 stocks at the start of the trading session.

The pharmaceutical company is listed as one of the worst-performing Ibex 35 stocks at the market's opening.

The pharmaceutical company appears among the worst-performing Ibex 35 stocks at the opening of the trading session.

The pharmaceutical company appears in a list of Ibex 35 stock quotes as one of the shares declining during the session.

The pharmaceutical company is listed as one of the worst-performing stocks at the opening of the Ibex 35 session.

The pharmaceutical company appears in a list of the worst-performing Ibex 35 stocks at the opening of a trading session.

The company appears as one of the worst-performing stocks at the opening of a session on the Spanish market.

Grifols is mentioned tangentially among Ibex 35 stocks in a report on the day's market opening.

The pharmaceutical company appears among the Ibex 35 stocks with the sharpest declines at the market opening.

It is mentioned as a historical example of a company targeted by a critical report from a short-selling investment firm.

The pharmaceutical company is mentioned as a historical case of a firm targeted by a short-selling investment fund.

The pharmaceutical company posts the sharpest daily drop on the Ibex 35 after suspending operations at its plasma clinics in Canada.

The company appears as one of the worst-performing stocks in the weekly closing of the Ibex 35.

The Catalan pharmaceutical company is the subject of an analysis on the reduction of short positions following improved financial results.

The company is mentioned as an example of a Spanish firm listed on Wall Street through depositary receipts.

It is mentioned as an example of a Spanish company that trades on Wall Street through depositary receipts.

The pharmaceutical company is listed among the Ibex 35 stocks with the biggest decline in Friday's session.

The company is listed among the Ibex 35 stocks with the largest declines in Friday's trading session.

The pharmaceutical company is listed among the stocks that recorded the largest declines in Friday's trading session.

The pharmaceutical company is mentioned as the worst-performing stock in the day's Ibex 35 session.

The pharmaceutical company is mentioned as the stock with the largest percentage drop in the Ibex 35 trading session.

The pharmaceutical company is listed among the shares that declined during the Ibex 35 trading session.

The pharmaceutical company appears among the Ibex 35 stocks with the largest percentage decline during the trading session.

The company appears among the Ibex 35 stocks with the largest percentage decline at the weekly market close.

The company appears among the stocks that recorded a slight gain in the Ibex 35 daily trading session.

The pharmaceutical company appears among the Ibex-35 stocks with a moderate gain during the daily trading session.

Grifols is listed as one of the IBEX 35 stocks with a moderate gain during the trading session.

The company appears in the Ibex 35 stock listing with a moderate gain during the trading session.

The company is listed among the stocks that posted gains during the day's trading session.

The company appears among the stocks that posted gains during the day's trading session.

The pharmaceutical company appears in a ranking on the share of international revenue among Ibex 35 companies.

The pharmaceutical company appears among the Ibex-35 stocks with a slight decline during the market's opening session.

The pharmaceutical company appears as one of the stocks with a slight drop at the Ibex 35 opening.

The pharmaceutical company is mentioned as one of the Ibex 35 stocks with the largest decline at the market opening.

The pharmaceutical company is listed among the Ibex 35 stocks with slight losses at the market opening.

The pharmaceutical company is listed among the Ibex 35 stocks showing slight declines at the market's opening.

The company appears as one of the Ibex 35 listed firms that posted a slight gain during a session in which the index hit record highs.

Grifols is listed among the shares that rose that day in the Ibex 35 session, without particular prominence in the news.

The company is listed among the best-performing Ibex 35 stocks during a session in which the index reached record highs.

The pharmaceutical company is listed among the Ibex 35 stocks with the highest percentage gain in the trading session.

The pharmaceutical company is the firm whose shares and financial instruments form part of the stake declared by an investment bank to the regulator.

The pharmaceutical company is the listed firm in which an investment bank has reported an increase in its shareholding.

The company appears among the stocks with the largest declines in the daily session of the Spanish stock index.

The pharmaceutical company appears as one of the biggest decliners in the Ibex-35 trading session.

The pharmaceutical company is the subject of an increased shareholding by a US investment bank.

Grifols is mentioned tangentially as one of the stocks that posted losses during the IBEX 35 trading session.

The pharmaceutical company appears among the Ibex 35 stocks that recorded declines during the day's trading session.

The pharmaceutical company appears among the worst-performing stocks in the Ibex 35 trading session.

The pharmaceutical company is listed among the Ibex 35 stocks with the largest decline in the day's trading session.

The pharmaceutical company is cited among Spanish firms with vaccine agreements in the United States that could be affected by a potential regulatory change.

The pharmaceutical company is the plaintiff in a New York court case against a short-seller fund over defamation.

The pharmaceutical company appears among the declining stocks of the Ibex 35 during a stable trading session.

The pharmaceutical company is cited as one of the stocks with the highest revaluation potential according to analysts.

The pharmaceutical company appears as the plaintiff in an ongoing defamation lawsuit against an investment fund.

The pharmaceutical company is the plaintiff in a New York lawsuit against an investment fund over defamation.

The company is cited as an example of a multinational pharmaceutical firm based in the Catalan biomedical cluster.

The company is mentioned as one of the multinational pharmaceutical firms based in Catalonia's biomedical cluster.

The company is mentioned as an example of a Spanish firm that generates added value through innovation and technology.

The pharmaceutical company is listed among several IBEX 35 firms highlighted by analysts for its improved half-year profit.

The pharmaceutical company is listed among the firms on the Spanish stock index identified by analysts as having the greatest upside potential.

The company is listed among the Ibex 35 firms with strong first-half results, without specific details of its own performance.

The pharmaceutical company appears in a list of stocks identified by analysts as having potential for share price growth.

The company is listed among the Ibex 35 stocks with a slight gain during a specific trading session.

The pharmaceutical company is listed among the Ibex 35 stocks that closed the session in positive territory.

The company appears in a list of Ibex 35 stocks with a slight gain during a trading session.

The company appears among the Ibex 35 stocks with the largest gains at the start of the trading session.

The pharmaceutical company is listed among the shares with the biggest gains at the opening of the Spanish stock index session.

The company appears among the best-performing stocks on the Ibex 35 at the opening of a trading session.

The company appears among the Ibex 35 stocks with the biggest gains at the start of the trading session.

The pharmaceutical company is listed among the Ibex 35 stocks that declined during a session of record highs for the index.

The company is listed among the lagging Ibex 35 stocks that analysts consider to have significant upside potential.

The pharmaceutical company is listed among the index stocks posting a slight decline during the session.

The company appears as one of the Ibex 35 stocks with a slight decline during the trading session.

Grifols is mentioned among the Ibex 35 stocks referenced when reporting on the trading session's performance.

The company is listed among the Ibex 35 stocks with a slight decline during a trading session marked by overall gains.

The company appears as one of the stocks with a slight decline during the day's trading session.

The pharmaceutical company appears among the Ibex 35 stocks with slight declines at the opening of a trading session.

The company is listed among the shares that rose during a historic session of the Spanish stock index.

The company is listed among the stocks that posted gains during a historic Ibex 35 trading session.

The company appears in a list of stocks on the Spanish benchmark index with the highest yearly gains.

The pharmaceutical company is presented as an example of integrating artificial intelligence into its biomedical research projects.

The company appears among the Ibex 35 stocks with the biggest gains in a trading session.

The pharmaceutical company is cited by financial analysts as one of several Spanish market stocks with growth potential.

The pharmaceutical company is listed among the Ibex 35 stocks that rose on the day the index reached a record high.

The pharmaceutical company is listed among the Ibex 35 stocks that posted a moderate gain during the day's trading session.

Grifols is mentioned tangentially in a list of stocks within a report on the Ibex 35's historic close above 20,000 points.

The company is mentioned as one of the stock market laggards this year within a general analysis of the Ibex 35.

The company is mentioned as an example of a Spanish firm exposed to potential regulatory changes in the United States.

The company is mentioned as an example of a Catalan business group affected by currency devaluation against the euro.

The company is cited as one of the IBEX 35 cases where female presence in executive bodies still falls short of the legally required minimum.

The company is assessed by a financial firm that positively values its ability to manage debt and improve results.

The pharmaceutical company appears as the processor of the plasma, which detected that a batch failed to meet proper temperature conditions.

The pharmaceutical company is listed among the stocks a fund manager considers to have growth potential.

The pharmaceutical company appears as one of the firms whose half-year results are analyzed and compared with other listed Spanish companies.

The pharmaceutical company is cited among several listed firms whose underlying business reportedly improved more than their half-year accounting profit shows.

The pharmaceutical company is listed among several large listed firms whose underlying business reportedly grew more than their accounting profit in the half-year.

Grifols is the main subject of the news as the seller of four US plasma collection centers, as part of a facility rationalization plan.

The pharmaceutical company is mentioned as one of the stocks that recorded a weekly gain of more than 5% in an investment portfolio.

The pharmaceutical company is listed as one of the stocks in an investment portfolio that posted weekly gains of over 5%.